



Supplemental Figures




Supplemental Figure 1. Effect of age on SARS-CoV-2 vaccine responses among IMID patients. (A) The distribution of age at enrollment is shown by treatment group: N=9 IMID untreated, N=46 anti-TNF, N=12 anti-IL17A, N=9 MTX/AZA, N=19 anti-TNF+MTZ/AZA, N=29 anti-IL-12/23, N=12 anti-IL-23, and N=25 healthy controls. (B) Age distribution is also shown by diagnoses, which are not mutually exclusive: N= 38 psoriasis, N=8 rheumatoid arthritis, N=8 ankylosing spondylitis, N=31 psoriatic arthritis, N=2 hidradenitis suppurativa, N=86 inflammatory bowel disease, N=15 other IMID, N=25 healthy controls. (C) Longitudinal analyses of the effect of age on humoral responses across one to four doses of vaccine in IMID patients: anti-RBD and anti-spike IgG levels ($\log_2(\text{BAU/mL})$) and neutralization of Wildtype SARS-CoV-2 ($\log_{10}(\text{ID}_{50})$). (D) Longitudinal analyses of the effect of age on cellular responses across one to four doses of vaccine in IMID patients: IL-2, IL-4, and IFN γ ($\log_{10}(\Delta\text{pg/mL})$). (C-D) IMID patients are divided into three age groups: 18-34 (black), 35-49 (green), and 50+ (purple). Mixed-effects multivariate linear regression models controlled for BMI and sex with an interaction term between timepoint and age group. An additional control for vaccine type was included in the regression models to compare responses between age groups: 18-34 vs 35-49 (green asterisks) and 18-34 vs 50+ (purple asterisks). * $p<0.05$; ** $p<0.01$; *** $p<0.001$; Δ , background subtracted; pg/mL, picogram per milliliter; PD, post dose

A




Supplemental Figure 2. Dosing interval by treatment group. Distribution of the days between dose1-dose2, dose2-dose3, and dose3-dose4 stratified by drug treatment group. * $p < 0.05$




Supplemental Figure 3. Longitudinal analyses of the magnitude of T cell cytokine and cytotoxic molecule responses pre and post one to four doses of SARS-CoV-2 mRNA vaccine. Timepoints are defined in Table 1. (A, B) Predicted mean T cell cytokines and cytotoxic molecules IL-17A, Granzyme A, Granzyme B, sFasL, Perforin ($\log_{10}(\Delta\text{pg/mL})$) from pre-vaccination to after four doses of vaccine. Mixed-effects linear regression models controlled for age, BMI, and sex (thick colored lines), with an interaction term between timepoint and group. Individual patients are plotted in thin lines. Groupings: healthy controls (black), IMID patients pooled (blue), TNF IMID (anti-TNF or anti-TNF+MTX/AZA treated) patients (red), and IMID patients not treated with anti-TNF (grey). Mixed-effects linear regression models with an additional control for vaccine type were used to compare groups: (A) IMID pooled vs healthy controls (blue asterisks); or (B) TNF IMID vs healthy controls (red asterisks). Sample sizes are listed in Supplemental Table 1. * $p<0.05$; ** $p<0.01$; *** $p<0.001$; Δ , background subtracted; pg/mL, picogram per milliliter; PD, post dose


A



Supplemental Figure 4. Longitudinal analyses of the stability of T cell cytokine and cytotoxic molecule responses post two to four doses of SARS-CoV-2 mRNA vaccine. (A) Timepoints are defined in Table 1. Predicted mean decrease of cytokine and cytotoxic molecules IL-17A, Granzyme A, Granzyme B, sFasL, and Perforin ($\log_{10}(\Delta pg/mL)$) in healthy controls, TNF IMID, and IMID patients not treated with anti-TNF between 2-4 weeks and 3-4 months after dose 2 (decrease between T3 and T4), after dose 3 (decrease between T5 and T6), and after dose 4 (decrease between T7 and T8). Mixed-effects linear regression models controlled for age, BMI, sex, and vaccine type, with an interaction term between timepoint and group. Mean decrease values that are significant ($pval < 0.05$) are colored in pink. Significant pairwise comparisons are indicated by asterisks and brackets. Sample sizes are listed in Supplemental Table 1. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; Δ : background subtracted; pg/mL: picogram per milliliter; PD: post dose



Supplemental Figure 5. T cell cytokine responses to Wildtype SARS-Cov-2 and Omicron (BA.1, BA.4/5) after three doses of SARS-CoV-2 mRNA vaccine. Timepoints are defined above each panel, as described in Table 1. (A) The release of cytokines in cell culture supernatant after 48 hours stimulation of PBMCs with SARS-CoV-2 spike peptide pools (lavender: Wildtype; orange: Omicron BA.1; blue: Omicron BA.4/5) were analyzed by LEGENDplex bead-based immunoassay. Depicted are responses in all participants (healthy and IMID) pooled, at two timepoints after the third dose of vaccine: T5 2-4wks_PD3 (2-4 weeks post dose 3) & T6 3-4M_PD3 (3-4 months post dose 3). Sample sizes are as follows: T5 (Wuhan vs Omicron BA.1), n = 46; T6 (Wuhan vs Omicron BA.1), n = 50; T6 (Wuhan vs Omicron BA.4/5), n = 52. Values are reported in pg/mL after subtracting background signal from wells containing PBMCs cultured with DMSO alone, as indicated by 'Δ'. Background subtracted values (Δpg/mL) were log₁₀ transformed for visualization purposes. Comparisons in paired IMID patients were conducted by paired Wilcoxon signed rank test after excluding healthy controls. *p<0.05, **p<0.01, ***p<0.001; ns, non-significant; PBMC, peripheral blood mononuclear cells; DMSO, dimethyl sulfoxide; pg/mL, picogram per millilitre; PD, post dose



Supplemental Figure 6. T cell cytotoxic responses to Wildtype SARS-CoV-2 and Omicron (BA.1, BA.4/5) after three doses of SARS-CoV-2 mRNA vaccine. Timepoints are defined above each panel, as described in Table 1. (A) The release of cytotoxic molecules in cell culture supernatant after 48 hours stimulation of PBMCs with SARS-CoV-2 spike peptide pools (lavender: Wildtype; orange: Omicron BA.1; blue: Omicron BA.4/5) were analyzed by LEGENDplex bead-based immunoassay. Depicted are responses in all participants (healthy and IMiD) pooled, at two timepoints after the third dose of vaccine: T5 2-4wks_PD3 (2-4 weeks post dose 3) & T6 3-4M_PD3 (3-4 months post dose 3). Sample sizes are as follows: T5 (Wuhan vs Omicron BA.1), $n = 46$; T6 (Wuhan vs Omicron BA.1), $n = 50$; T6 (Wuhan vs Omicron BA.4/5), $n = 52$. Values are reported in pg/mL after subtracting background signal from wells containing PBMCs cultured with DMSO alone, as indicated by 'Δ'. Background subtracted values (Δpg/mL) were \log_{10} transformed for visualization purposes. Comparisons in paired IMiD patients were conducted by paired Wilcoxon signed rank test after excluding healthy controls. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; ns, non-significant; PBMC, peripheral blood mononuclear cells; DMSO, dimethyl sulfoxide; pg/mL, picogram per millilitre; PD, post dose

Supplemental Tables

Supplemental Table S1. Samples sizes used in multivariate analyses

	T1: Pre	T2: 2- 4wks PD1	T3: 2- 4wks PD2	T4: 3- 4M PD2	T5: 2- 4wks PD3	T6: 3- 4M PD3	T7: 2- 4wks PD4	T8: 3- 4M PD4
IgG								
Healthy controls	15	17	21	11	5	6		
IMID pooled	94	112	103	84	52	41	24	19
Non-TNF IMID	42	59	55	51	29	26	13	11
Untreated	9	9	9	9	5	6	0	0
Anti-IL17A	3	6	6	6	6	5	4	3
MTX/AZA	3	7	7	4	2	1	1	2
Anti-IL12/23	26	27	23	22	11	11	6	5
Anti-IL23	1	10	10	10	5	3	2	1
TNF IMID	52	53	48	33	23	15	11	8
Anti-TNF	37	37	34	23	16	9	5	3
Anti-TNF + MTZ/AZA	15	16	14	10	7	6	6	5
Neutralizing (Wildtype)								
Healthy controls			21	9	5	6		
IMID pooled			103	79	43	40	16	17
Non-TNF IMID			55	48	24	25	8	11
Untreated			9	9	5	5	0	0
Anti-IL17A			6	5	5	5	3	3
MTX/AZA			7	3	1	1	0	2
Anti-IL12/23			23	22	8	11	4	5
Anti-IL23			10	9	5	3	1	1
TNF IMID			48	31	19	15	8	6
Anti-TNF			34	22	14	9	4	2
Anti-TNF + MTZ/AZA			14	9	5	6	4	4
T cell cytokines and cytotoxic molecules								
Healthy controls	14	13	17	8	4	6		
IMID pooled	85	95	96	75	49	39	25	20
Non-TNF IMID	36	48	50	46	27	26	14	11
Untreated	9	9	9	9	5	6	0	0

Anti-IL17A	3	5	4	5	6	5	4	3
MTX/AZA	3	5	6	3	1	1	1	2
Anti-IL12/23	20	20	22	21	10	11	7	5
Anti-IL23	1	9	9	8	5	3	2	1
TNF IMID	49	47	46	29	22	13	11	9
Anti-TNF	36	33	32	20	14	7	5	4
Anti-TNF + MTZ/AZA	13	14	14	9	8	6	6	5

Bolded values represent sums of the rows below (i.e., IMID pooled totals are the sum of Non-TNF IMID and TNF IMID totals).

Abbreviations: AZA: azathioprine; IL: Interleukin; IMID: Immune-Mediated Inflammatory Diseases; M: months; MTX: Methotrexate; PD: Post dose; TNF: Tumor necrosis factor; wks: weeks

Supplemental Table S2. Sample sizes used in comparisons of neutralization of Wildtype SARS-CoV-2 versus Omicron BA.1/BA.5.

Neutralizing	T4: 3-4M_PD2	T5: 2-4wks_PD3	T6: 3-4M_PD3	T7: 2-4wks_PD4	T8: 3-4M_PD4
Wildtype vs Omicron BA.1					
Healthy controls	9	5	6		
Non-TNF IMID	48	24	25	8	11
TNF IMID	32	19	15	9	6
Wildtype vs Omicron BA.5					
Healthy controls		5	6		
Non-TNF IMID		24	25	8	11
TNF IMID	4	19	15	9	6

Supplemental Table S3. Anti-spike and anti-RBD IgG levels

	Anti-spike - log ₂ (BAU/mL)			Anti-RBD - log ₂ (BAU/mL)		
	Healthy controls	Non-TNF IMID	Anti-TNF	Healthy controls	Non-TNF IMID	Anti-TNF
T1: Pre - N	15	42	52	15	42	52
Median (IQR)	0.8 (-0.8 - 1.5)	0.7 (0.3 - 1.3)	0.8 (0.4 - 1.6)	0.6 (0.6 - 0.6)	0.6 (0.6 - 0.6)	0.6 (0.6 - 0.6)
Upper limit - N (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
T2: 2-4wks_PD1 - N	17	59	53	16	58	53
Median (IQR)	8.3 (7.9 - 8.9)	7.6 (6.5 - 8.8)	6.4 (5.4 - 7.2)	7.6 (7.0 - 8.3)	7.2 (6.4 - 7.8)	6.1 (4.8 - 7.1)
Upper limit - N (%)	0 (0.0)	2 (3.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
T3: 2-4wks_PD2 - N	21	55	48	21	55	48
Median (IQR)	10.6 (10.6 - 10.6)	10.6 (10.6 - 10.6)	10.5 (9.2 - 10.6)	11.7 (10.6 - 12.1)	12.0 (11.3 - 12.1)	10.5 (9.1 - 11.9)
Upper limit - N (%)	17 (81.0)	45 (81.8)	24 (50.0)	9 (42.9)	25 (45.5)	10 (20.8)
T4: 3-4M_PD2 - N	11	51	33	11	51	33
Median (IQR)	9.7 (9.1 - 10.0)	9.2 (7.9 - 9.7)	5.7 (5.4 - 7.3)	9.5 (9.2 - 10.5)	8.7 (7.5 - 10.1)	6.7 (5.1 - 7.2)
Upper limit - N (%)	0 (0.0)	2 (3.9)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
T5: 2-4wks_PD3 - N	5	29	23	5	29	23
Median (IQR)	10.6 (10.6 - 10.6)	10.6 (10.5 - 10.6)	10.6 (9.2 - 10.6)	11.6 (11.3 - 11.7)	11.2 (10.4 - 11.8)	10.5 (8.4 - 11.5)
Upper limit - N (%)	5 (100.0)	21 (72.4)	13 (56.5)	1 (20.0)	4 (13.8)	2 (8.7)
T6: 3-4M_PD3 - N	6	26	15	6	26	14
Median (IQR)	10.5 (9.9 - 10.6)	9.6 (9.0 - 10.5)	8.1 (6.1 - 9.2)	10.0 (9.8 - 10.8)	9.3 (8.5 - 10.3)	8.1 (7.2 - 8.6)
Upper limit - N (%)	3 (50.0)	6 (23.1)	1 (6.7)	0 (0.0)	1 (3.8)	0 (0.0)
T7: 2-4wks_PD4 - N		13	11		13	11
Median (IQR)		10.6 (10.6 - 10.6)	9.1 (8.2 - 10.6)		11.0 (10.7 - 11.7)	9.0 (8.6 - 10.4)
Upper limit - N (%)		11 (84.6)	3 (27.3)		2 (15.4)	1 (9.1)
T8: 3-4M_PD4 - N		11	8		11	8
Median (IQR)		9.8 (9.4 - 10.6)	8.6 (6.7 - 9.6)		9.1 (8.5 - 10.7)	7.7 (7.1 - 9.5)
Upper limit - N (%)		4 (36.4)	1 (12.5)		0 (0.0)	0 (0.0)

Abbreviations: BAU/mL: Binding antibody units per milliliter; IMID: Immune-Mediated Inflammatory Diseases; IQR: Inter-quartile range; M: months; PD: Post dose; TNF: Tumor necrosis factor; wks: weeks

Supplemental Table S4. Neutralization titers

	Wild Type Neutralization - Log ₁₀ (ID50)			Omicron BA.1 Neutralization - Log ₁₀ (ID50)			Omicron BA.5 Neutralization - Log ₁₀ (ID50)		
	Healthy controls	Non-TNF IMID	Anti-TNF	Healthy controls	Non-TNF IMID	Anti-TNF	Healthy controls	Non-TNF IMID	Anti-TNF
T3: 2-4wks_PD2 - N	21	55	48						
Median (IQR)	3.6 (3.2 - 3.9)	3.5 (3.3 - 3.9)	2.9 (2.4 - 3.4)						
Lower limit - N (%)	0 (0.0)	0 (0.0)	1 (2.1)						
T4: 3-4M_PD2 - N	9	48	31	9	48	31			
Median (IQR)	3.2 (3.0 - 3.2)	2.5 (2.2 - 2.8)	1.6 (0.0 - 2.0)	2.1 (1.3 - 2.2)	1.1 (0.0 - 1.7)	0.0 (0.0 - 0.0)			
Lower limit - N (%)	0 (0.0)	1 (2.1)	8 (25.8)	1 (11.1)	17 (35.4)	25 (80.6)			
T5: 2-4wks_PD3 - N	5	24	19	5	24	19	5	24	19
Median (IQR)	3.8 (3.6 - 3.9)	3.5 (3.3 - 3.6)	3.6 (2.9 - 3.9)	2.9 (2.8 - 3.3)	2.5 (2.3 - 2.7)	2.5 (0.9 - 3.0)	2.9 (2.6 - 3.1)	2.4 (2.2 - 2.6)	2.2 (1.8 - 2.7)
Lower limit - N (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	4 (21.1)	0 (0.0)	0 (0.0)	1 (5.3)
T6: 3-4M_PD3 - N	6	25	15	6	25	15	6	25	15
Median (IQR)	3.7 (3.4 - 3.9)	3.1 (2.9 - 3.2)	2.7 (2.2 - 3.1)	2.6 (2.5 - 3.1)	2.0 (1.8 - 2.3)	1.6 (0.0 - 1.8)	2.3 (2.2 - 2.6)	1.8 (1.4 - 2.1)	0.0 (0.0 - 1.6)
Lower limit - N (%)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	5 (33.3)	0 (0.0)	3 (12.0)	8 (53.3)
T7: 2-4wks_PD4 - N		8	8		8	8		8	8
Median (IQR)		3.6 (3.1 - 3.8)	3.0 (2.2 - 3.5)		2.5 (1.3 - 2.8)	1.2 (1.0 - 2.3)		2.5 (2.0 - 3.0)	1.6 (1.0 - 2.3)
Lower limit - N (%)		0 (0.0)	1 (12.5)		1 (12.5)	1 (12.5)		0 (0.0)	1 (12.5)
T8: 3-4M_PD4 - N		11	6		11	6		11	6
Median (IQR)		3.4 (2.9 - 3.6)	2.3 (2.1 - 2.9)		2.2 (1.0 - 2.4)	1.3 (1.2 - 1.6)		2.1 (1.6 - 2.7)	1.2 (0.0 - 1.6)
Lower limit - N (%)		0 (0.0)	0 (0.0)		1 (9.1)	1 (16.7)		1 (9.1)	2 (33.3)

Abbreviations: ID50: 50% inhibitory dose; IMID: Immune-Mediated Inflammatory Diseases; IQR: Inter-quartile range; M: months; PD: Post dose; TNF: Tumor necrosis factor; wks: weeks

Supplemental Table S5. Comparisons (p-value) of peak humoral and cellular responses after successive doses of vaccination

Humoral Responses				
Anti-spike IgG - log₂(BAU/mL)	Healthy Controls	IMID Pooled	TNF IMID	Non-TNF IMID
Dose 1 vs Dose 2 (T2 vs T3)	0.000	0.000	0.000	0.000
Dose 2 vs Dose 3 (T3 vs T5)	0.563	0.855	0.740	0.487
Dose 3 vs Dose 4 (T5 vs T7)		0.488	0.481	0.688
Anti-RBD IgG - log₂(BAU/mL)				
Dose 1 vs Dose 2 (T2 vs T3)	0.000	0.000	0.000	0.000
Dose 2 vs Dose 3 (T3 vs T5)	0.822	0.105	0.366	0.187
Dose 3 vs Dose 4 (T5 vs T7)		0.312	0.283	0.702
Neutralization of Wildtype - log₁₀(ID50)				
Dose 1 vs Dose 2 (T2 vs T3)				
Dose 2 vs Dose 3 (T3 vs T5)		0.019	0.005	0.353
Dose 3 vs Dose 4 (T5 vs T7)		0.111	0.071	0.484
Cellular Responses				
IL-2 - log₁₀(Δpg/mL)	Healthy Controls	IMID Pooled	TNF IMID	Non-TNF IMID
Dose 1 vs Dose 2 (T2 vs T3)	0.081	0.026	0.003	0.846
Dose 2 vs Dose 3 (T3 vs T5)	0.195	0.000	0.000	0.000
Dose 3 vs Dose 4 (T5 vs T7)		0.583	0.694	0.237
IL-4 - log₁₀(Δpg/mL)				
Dose 1 vs Dose 2 (T2 vs T3)	0.013	0.000	0.000	0.000
Dose 2 vs Dose 3 (T3 vs T5)	0.141	0.861	0.554	0.775
Dose 3 vs Dose 4 (T5 vs T7)		0.018	0.027	0.268
IFNγ - log₁₀(Δpg/mL)				
Dose 1 vs Dose 2 (T2 vs T3)	0.449	0.395	0.365	0.748
Dose 2 vs Dose 3 (T3 vs T5)	0.609	0.233	0.110	0.838
Dose 3 vs Dose 4 (T5 vs T7)		0.776	0.763	0.852

Abbreviations: ID50: 50% inhibitory dose; BAU/ml: binding antibody units per milliliter; Δ: delta, background subtracted; pg/mL: picogram per milliliter; colored in red: p-value < 0.05